- Home
- EPSM vs OABI Comparison
EPSM vs OABI Comparison
Compare EPSM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- OABI
- Stock Information
- Founded
- EPSM 2010
- OABI 2012
- Country
- EPSM China
- OABI United States
- Employees
- EPSM N/A
- OABI N/A
- Industry
- EPSM
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- OABI Health Care
- Exchange
- EPSM Nasdaq
- OABI Nasdaq
- Market Cap
- EPSM 185.6M
- OABI 185.9M
- IPO Year
- EPSM 2025
- OABI N/A
- Fundamental
- Price
- EPSM $16.71
- OABI $1.41
- Analyst Decision
- EPSM
- OABI Strong Buy
- Analyst Count
- EPSM 0
- OABI 3
- Target Price
- EPSM N/A
- OABI $7.00
- AVG Volume (30 Days)
- EPSM 495.4K
- OABI 935.9K
- Earning Date
- EPSM 01-01-0001
- OABI 05-08-2025
- Dividend Yield
- EPSM N/A
- OABI N/A
- EPS Growth
- EPSM N/A
- OABI N/A
- EPS
- EPSM 0.02
- OABI N/A
- Revenue
- EPSM $12,518,070.00
- OABI $26,744,000.00
- Revenue This Year
- EPSM N/A
- OABI N/A
- Revenue Next Year
- EPSM N/A
- OABI $40.06
- P/E Ratio
- EPSM $812.57
- OABI N/A
- Revenue Growth
- EPSM N/A
- OABI 27.07
- 52 Week Low
- EPSM $4.23
- OABI $1.22
- 52 Week High
- EPSM $17.63
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- OABI 39.84
- Support Level
- EPSM N/A
- OABI $1.22
- Resistance Level
- EPSM N/A
- OABI $1.41
- Average True Range (ATR)
- EPSM 0.00
- OABI 0.09
- MACD
- EPSM 0.00
- OABI 0.01
- Stochastic Oscillator
- EPSM 0.00
- OABI 46.34
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.